×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ITOS – iteos therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ITOS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
09:09 am
itos
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/15
08:02 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
11/13
12:45 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
11/12
07:00 am
itos
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Low
Report
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/24
07:00 am
itos
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
Low
Report
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
9/16
08:03 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
High
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
9/15
04:02 am
itos
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT [Seeking Alpha]
High
Report
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT [Seeking Alpha]
9/14
02:37 am
itos
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients [Yahoo! Finance]
High
Report
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
08:28 pm
itos
Form SC 13G iTeos Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SC 13G iTeos Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/19
07:59 pm
itos
Form 4 iTeos Therapeutics, Inc. For: Nov 19 Filed by: Gall Matthew
Low
Report
Form 4 iTeos Therapeutics, Inc. For: Nov 19 Filed by: Gall Matthew
11/19
09:58 am
itos
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
Low
Report
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
11/18
09:57 pm
itos
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
Low
Report
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
11/14
06:04 pm
itos
Form SC 13G/A iTeos Therapeutics, Inc. Filed by: EcoR1 Capital, LLC
Low
Report
Form SC 13G/A iTeos Therapeutics, Inc. Filed by: EcoR1 Capital, LLC
11/12
09:22 am
itos
Form 10-Q iTeos Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q iTeos Therapeutics, Inc. For: Sep 30
11/8
02:19 pm
itos
Form SC 13G/A iTeos Therapeutics, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A iTeos Therapeutics, Inc. Filed by: BlackRock, Inc.
11/4
07:00 am
itos
Form 8-K iTeos Therapeutics, Inc. For: Oct 31
Low
Report
Form 8-K iTeos Therapeutics, Inc. For: Oct 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: